Floatz logo

Epi-506

Prostatic Diseases

ESSA PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Prostatic Diseases cohort.

Asset / SponsorPhaseRating
DINITROGEN MONOXIDE
Beth Israel Deaconess Medical Center
Phase 4BB
Oxygen
Beth Israel Deaconess Medical Center
Phase 4BB
Epoetin Alfa
Janssen-Ortho Inc., Canada
Phase 3B
Nivolumab
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2B
Gnrh
Memorial Sloan Kettering Cancer Center
Phase 2B

View all 27 →

Same molecule, other indications

Epi-506 is also rated in:

male reproductive system neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
male reproductive system disorderDormant
CC
Indicative ·
47 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →